Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVI-4065
- Development stage
- Phase 1
- Lead developer
- Sarepta Therapeutics
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
AVI-4065 is a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide developed as an investigational antiviral drug for the treatment of hepatitis C virus (HCV) infection. It was designed to inhibit HCV replication by irreversibly binding to the viral genome, thereby preventing viral protein synthesis and subsequent virus replication. The drug was developed using proprietary NeuGene antisense technology and underwent early-phase clinical trials that demonstrated favorable safety and tolerability profiles but did not achieve the therapeutic threshold required for efficacy at tested doses. Development of AVI-4065 for hepatitis C has been discontinued[1][2][4][6][7].
02
Targets
HCV RNA (Hepatitis C virus RNA)
Beyond the preview
Go deeper on AVI-4065.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVI-4065.